Healthy Skepticism Library item: 17255

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

Sales Through Retail Pharmacies (Twelve months to November 2009*)
2010
http://view.respond.imshealth.com/?j=fe6215717c61057a7014&m=fef31377726304&ls=fdfa17757666017475127374&l=fe9615727662037

Full text:

NORTH AMERICA $232.5 billion up 5%
U.S.A. $216.1 billion up 5%
CANADA $16.3 billion up 7%

EUROPE (TOP 5) $108.5 billion up 3%
GERMANY $34.5 billion up 5%
FRANCE $29.1 billion up 1%
UK $13.4 billion up 3%
ITALY $16.4 billion up 2%
SPAIN $14.9 billion up 4%

JAPAN (including hospitals) $79.5 billion up 6%

CHINA (hospital) $24.7 billion up 27%

LATIN AMERICA (TOP 3) $22.9 billion up 11%
BRAZIL $12.5 billion up 14%
MEXICO $7.04 billion up 1%
ARGENTINA $3.3 billion up 22%
VENEZUELA $5.6 billion up 32%

AUSTRALIA/NZ $7.6 billion up 7%

The top 5 therapy classes at ATC3 level in the 12 months to November 2009 were:
1. C10A – Cholesterol & trigly. regulators
2. A2B – Antiulcerants
3. N6A – Antidepressants & mood stabilisers
4. N5A – Antipsychotics
5. C9C – Angioten-II Antag, Plain

The top 5 products in the 12 months to November 2009 were:
1. Lipitor
2. Plavix
3. Nexium
4. Seretide
5. Crestor

The top 5 corporations in the 12 months to November 2009 were:
1. Pfizer
2. AstraZeneca
3. Novartis
4. GlaxoSmithKline
5. Sanofi-Aventis